## Claims

1. A double-stranded nucleic acid for inhibiting expression of complement component C3, wherein the nucleic acid comprises a first strand and a second strand, wherein the first strand sequence comprises a sequence of at least 15 nucleotides differing by no more than 3 nucleotides from any one of the sequences SEQ ID NO: 370, 364, 365, 366, 368, 372, 377 or 416.

2. A double-stranded nucleic acid that is capable of inhibiting expression of complement component C3 for use as a medicament, wherein the nucleic acid comprises a first strand and a second strand.

3. The nucleic acid of any of the preceding claims, wherein the first strand and the second strand form a duplex region of from 17-25 nucleotides in length.

4. The nucleic acid of any of the preceding claims, wherein the nucleic acid mediates RNA interference.

5. The nucleic acid of any of the preceding claims, wherein at least one nucleotide of the first and/or second strand is a modified nucleotide, preferably the modified nucleotide is a non-naturally occurring nucleotide such as a 2'-F modified nucleotide.

6. The nucleic acid of any of the preceding claims, wherein at least nucleotides 2 and 14 of the first strand are modified by a first modification, the nucleotides being numbered consecutively starting with nucleotide number 1 at the 5' end of the first strand.

7. The nucleic acid of any of the previous claims, wherein the first strand has a terminal 5' (E)-vinylphosphonate nucleotide at its 5' end.

8. The nucleic acid of any of the preceding claims, wherein the nucleic acid comprises a phosphorothioate linkage between the terminal two or three 3' nucleotides and/or 5' nucleotides of the first and/or the second strand and preferably wherein the linkages between the remaining nucleotides are phosphodiester linkages.

9. The nucleic acid of any of the preceding claims, comprising a phosphorodithioate linkage between each of the two, three or four terminal nucleotides at the 3' end of the first strand and/or comprising a phosphorodithioate linkage between each of the two, three or four

terminal nucleotides at the 3' end of the second strand and/or a phosphorodithioate linkage between each of the two, three or four terminal nucleotides at the 5' end of the second strand and comprising a linkage other than a phosphorodithioate linkage between the two, three or four terminal nucleotides at the 5' end of the first strand.

10. The nucleic acid of any of the preceding claims, wherein the nucleic acid is conjugated to a ligand.

11. The nucleic acid of claim 10, wherein the ligand comprises (i) one or more N-acetyl galactosamine (GalNAc) moieties or derivatives thereof, and (ii) a linker, wherein the linker conjugates the at least one GalNAc moiety or derivative thereof to the nucleic acid.

12. A composition comprising a nucleic acid of any of the previous claims and a solvent and/or a delivery vehicle and/or a physiologically acceptable excipient and/or a carrier and/or a salt and/or a diluent and/or a buffer and/or a preservative and/or a further therapeutic agent selected from the group comprising an oligonucleotide, a small molecule, a monoclonal antibody, a polyclonal antibody and a peptide.

13. A nucleic acid of any of claims 1 and 3-11 or a composition of claim 12 for use as a medicament.

14. A nucleic acid of any of claims 1 and 3-11 or a composition of claim 12 for use in the prevention, decrease of the risk of suffering from, or treatment of a disease, disorder or syndrome, wherein the disease, disorder or syndrome is preferably a complement-mediated disease, disorder or syndrome.

15. Use of a nucleic acid of any of claims 1 and 3-11 or a composition of claim 12 in the prevention, decrease of the risk of suffering from, or treatment of a disease, disorder or syndrome, wherein the disease, disorder or syndrome is preferably selected from the group comprising C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD) and IgA nephropathy (IgA N).

16. Method of preventing, decreasing the risk of suffering from, or treating a disease, disorder or syndrome comprising administering a pharmaceutically effective amount of a nucleic acid of any of claims 1 and 3-11 or a composition of claim 12 to an individual in need of treatment, wherein the disease, disorder or syndrome is preferably selected

from the group comprising C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD) and IgA nephropathy (IgA N).